Targeting SIRPα with BMS-986351 led to potent inhibition of SIRPα-CD47 binding and increased phagocytic activity in in vitro models of colorectal cancer, SCCHN, and DLBCL cell lines. Here, SIRPA is linked to head and neck squamous cell carcinoma.